ADVERUM BIOTECHNOLOGIES, INC. Financials Adverum Biotechnologies, Inc.
Equities
ADVM
US00773U2078
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.19 USD | -2.13% |
|
-18.96% | +22.08% |
| Mar. 21 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
| Mar. 19 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 744.1 | 1,057 | 172.7 | 57.79 | 76.05 | 190.7 | - | - |
| Enterprise Value (EV) 1 | 578 | 626.9 | -132.4 | -127.8 | -20.47 | 42 | 55.22 | 190.7 |
| P/E ratio | -11.4 x | -7.86 x | -1.19 x | -0.37 x | -0.65 x | -1.7 x | -1.61 x | -1.54 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2,976 x | - | 23 x | - | 21.1 x | - | 19.1 x | 12.7 x |
| EV / Revenue | 2,312 x | - | -17.7 x | - | -5.69 x | - | 5.52 x | 12.7 x |
| EV / EBITDA | -8.63 x | -5.51 x | 0.94 x | 0.85 x | 0.17 x | -0.38 x | -0.37 x | -1.2 x |
| EV / FCF | -8.45 x | -6.88 x | 1.08 x | 1.07 x | 0.22 x | -0.54 x | -1.06 x | -0.94 x |
| FCF Yield | -11.8% | -14.5% | 92.8% | 93.8% | 448% | -184% | -94.2% | -107% |
| Price to Book | 4.22 x | 2.12 x | 0.55 x | 0.32 x | 0.91 x | 1.46 x | 1.8 x | - |
| Nbr of stocks (in thousands) | 6,459 | 9,748 | 9,815 | 9,973 | 10,103 | 20,755 | - | - |
| Reference price 2 | 115.2 | 108.4 | 17.60 | 5.795 | 7.528 | 9.190 | 9.190 | 9.190 |
| Announcement Date | 3/12/20 | 3/1/21 | 3/29/22 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.25 | - | 7.5 | - | 3.6 | - | 10 | 15 |
| EBITDA 1 | -66.97 | -113.8 | -141.5 | -150.6 | -118.3 | -111 | -151 | -159 |
| EBIT 1 | -68.54 | -118 | -146.1 | -157.1 | -124 | -116.9 | -147.5 | -177 |
| Operating Margin | -27,418% | - | -1,948.29% | - | -3,444.19% | - | -1,474.7% | -1,179.94% |
| Earnings before Tax (EBT) 1 | -64.49 | -116.4 | -145.5 | -154.5 | -118.2 | -112.2 | -141.4 | -178.1 |
| Net income 1 | -64.49 | -117.5 | -145.5 | -154.5 | -117.2 | -111.2 | -142.7 | -172.8 |
| Net margin | -25,794.4% | - | -1,940.53% | - | -3,254.58% | - | -1,427.23% | -1,152.21% |
| EPS 2 | -10.10 | -13.80 | -14.80 | -15.60 | -11.60 | -5.402 | -5.717 | -5.978 |
| Free Cash Flow 1 | -68.42 | -91.14 | -123 | -119.9 | -91.71 | -77.26 | -52.01 | -203.6 |
| FCF margin | -27,366.8% | - | -1,639.39% | - | -2,547.5% | - | -520.1% | -1,357.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/29/22 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 3.6 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -37.56 | -33.1 | -36.71 | -42.42 | -39.25 | -32.23 | -28.65 | -31.53 | -33.02 | -25.15 | -27 | -27 | -28 | -29 | -34 |
| EBIT 1 | -38.52 | -34.42 | -38.13 | -44.02 | -41.04 | -33.94 | -30.24 | -33.06 | -34.53 | -26.16 | -26.95 | -28.2 | -29.88 | -31.84 | -33.88 |
| Operating Margin | - | - | - | - | - | - | -839.97% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -38.36 | -34.41 | -37.89 | -43.74 | -40.11 | -32.72 | -29.04 | -31.49 | -32.87 | -24.85 | -25.83 | -26.77 | -28.76 | -30.81 | -31.5 |
| Net income 1 | -38.36 | -34.41 | -37.91 | -43.76 | -40.13 | -32.74 | -29.06 | -31.51 | -32.88 | -23.71 | -25.81 | -26.77 | -28.51 | -30.04 | -32.62 |
| Net margin | - | - | - | - | - | - | -807.11% | - | - | - | - | - | - | - | - |
| EPS 2 | -3.900 | -3.500 | -3.800 | -4.400 | -4.000 | -3.300 | -2.900 | -3.100 | -3.300 | -2.300 | -1.422 | -1.316 | -1.334 | -1.370 | -1.550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/29/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/18/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 166 | 430 | 305 | 186 | 96.5 | 149 | 136 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -68.4 | -91.1 | -123 | -120 | -91.7 | -77.3 | -52 | -204 |
| ROE (net income / shareholders' equity) | - | -38.6% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 27.30 | 51.00 | 32.30 | 18.10 | 8.280 | 6.300 | 5.100 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 19.2 | 11.8 | 15.1 | 11.8 | 0.81 | 0.8 | 0.7 | 0.6 |
| Capex / Sales | 7,698.8% | - | 201.64% | - | 22.44% | - | 7% | 4% |
| Announcement Date | 3/12/20 | 3/1/21 | 3/29/22 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.19
USD
Average target price
40
USD
Spread / Average Target
+335.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.08% | 191M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ADVM Stock
- Financials Adverum Biotechnologies, Inc.
